Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 18/20 | 1.00 |
| ▸ | HDAC4 | P56524 | 6/20 | 0.67 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.57 |
| ▸ | HDAC7 | Q8WUI4 | 4/20 | 0.57 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.57 |
| ▸ | HDAC10 | Q969S8 | 4/20 | 0.57 |
| ▸ | HDAC11 | Q96DB2 | 4/20 | 0.57 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.57 |
| ▸ | HDAC9 | Q9UKV0 | 4/20 | 0.57 |
| ▸ | HDAC5 | Q9UQL6 | 4/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5048820 | 1.00 | HDAC1 (1.00) | HDAC1HDAC4HDAC8MEN1MAPT | |
| SCHEMBL5020638 | 1.00 | HDAC1 (1.00) | HDAC1HDAC4HDAC8MEN1MAPT | |
| SCHEMBL6749952 | 1.00 | HDAC1 (1.00) | HDAC1HDAC4HDAC8MEN1MAPT | |
| SCHEMBL13776415 | 0.91 | HDAC1 (0.87) | HDAC1HDAC4HDAC8HDAC3HDAC7 | |
| SCHEMBL14188745 | 0.89 | HDAC1 (0.80) | HDAC1HDAC4HDAC8MEN1MAPT | |
| SCHEMBL5020640 | 0.89 | HDAC1 (1.00) | HDAC1HDAC4HDAC8HDAC3HDAC7 | |
| SCHEMBL5046654 | 0.89 | HDAC1 (1.00) | HDAC1HDAC4HDAC8HDAC3HDAC7 | |
| SCHEMBL14188338 | 0.89 | HDAC1 (0.79) | HDAC1HDAC4HDAC8HDAC3HDAC7 | |
| SCHEMBL5047304 | 0.89 | HDAC1 (1.00) | HDAC1HDAC4HDAC8HDAC3HDAC7 | |
| SCHEMBL5020771 | 0.89 | HDAC1 (0.79) | HDAC1HDAC4HDAC8HDAC3HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040072770-A1 | Methods for specifically inhibiting histone deacetylase-7 and 8 | METHYLGENE, INC. (CA) | 2004-04-15 | — | — | US | claimed |
| US-20240325398-A1 | COMBINATION THERAPIES | INFINITY PHARMACEUTICALS, INC. | 2024-10-03 | — | — | US | disclosed |
| US-20200338083-A1 | COMBINATION THERAPIES | INFINITY PHARMACEUTICALS, INC. | 2020-10-29 | — | — | US | disclosed |
| US-20170348314-A1 | COMBINATION THERAPIES | HCR COLLATERAL MANAGEMENT, LLC | 2017-12-07 | — | — | US | disclosed |
| US-20150320754-A1 | COMBINATION THERAPIES | INFINITY PHARMACEUTICALS, INC. | 2015-11-12 | — | — | US | disclosed |
| US-9115345-B2 | MicroRNA induction of pluripotential stem cells and uses thereof | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2015-08-25 | — | — | US | disclosed |
| US-20130035374-A1 | MicroRNA induction of pluripotential stem cells and uses thereof | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2013-02-07 | — | — | US | disclosed |
| EP-2419737-A2 | HISTONE MODIFICATION PATTERNS FOR CLINICAL DIAGNOSIS AND PROGNOSIS OF CANCER | The Regents of the University of California (US) | 2012-02-22 | — | — | EP | disclosed |
| WO-2011133288-A9 | MICRORNA INDUCTION OF PLURIPOTENTIAL STEM CELLS AND USES THEREOF | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2011-12-22 | — | — | WO | disclosed |
| WO-2011133288-A1 | MICRORNA INDUCTION OF PLURIPOTENTIAL STEM CELLS AND USES THEREOF | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2011-10-27 | — | — | WO | disclosed |
| WO-2010120942-A2 | HISTONE MODIFICATION PATTERNS FOR CLINICAL DIAGNOSIS AND PROGNOSIS OF CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-10-21 | — | — | WO | disclosed |
| US-20040072770-A1 | Methods for specifically inhibiting histone deacetylase-7 and 8 | METHYLGENE, INC. (CA) | 2004-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200338083-A1 | COMBINATION THERAPIES | HDAC1, HDAC4, HDAC2 | HDAC1 1/4885HDAC4 2/4885HDAC8 9/4885 |
| US-20150320754-A1 | COMBINATION THERAPIES | HDAC1, HDAC4, HDAC2 | HDAC1 1/4885HDAC4 2/4885HDAC8 9/4885 |
| US-20170348314-A1 | COMBINATION THERAPIES | HDAC1, HDAC4, HDAC2 | HDAC1 1/4885HDAC4 2/4885HDAC8 9/4885 |
| US-20240325398-A1 | COMBINATION THERAPIES | HDAC1, HDAC4, HDAC2 | HDAC1 1/4885HDAC4 2/4885HDAC8 9/4885 |
| US-20040072770-A1 | Methods for specifically inhibiting histone deacetylase-7 and 8 | HDAC8, HDAC7, HDAC1 | HDAC1 3/4885HDAC4 10/4885HDAC8 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.